Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Non-Current Assets (2021 - 2025)

Historic Non-Current Assets for Inhibikase Therapeutics (IKT) over the last 5 years, with Q3 2025 value amounting to $1.1 million.

  • Inhibikase Therapeutics' Non-Current Assets rose 46641.95% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 4293.12%. This contributed to the annual value of $148537.0 for FY2024, which is 4975.05% down from last year.
  • Per Inhibikase Therapeutics' latest filing, its Non-Current Assets stood at $1.1 million for Q3 2025, which was up 46641.95% from $58605.0 recorded in Q2 2025.
  • Over the past 5 years, Inhibikase Therapeutics' Non-Current Assets peaked at $1.1 million during Q3 2025, and registered a low of $2783.0 during Q1 2021.
  • Moreover, its 5-year median value for Non-Current Assets was $260264.0 (2024), whereas its average is $318834.6.
  • In the last 5 years, Inhibikase Therapeutics' Non-Current Assets skyrocketed by 74386.97% in 2023 and then tumbled by 7383.67% in 2025.
  • Inhibikase Therapeutics' Non-Current Assets (Quarter) stood at $2783.0 in 2021, then soared by 20208.12% to $565175.0 in 2022, then tumbled by 47.7% to $295599.0 in 2023, then crashed by 49.75% to $148537.0 in 2024, then soared by 612.22% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $58605.0 for Q2 2025, and $116564.0 during Q1 2025.